https://eureka.patsnap.com/resources/blog/rd-blog/stapled-and-constrained-peptides-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Macrocyclic Compounds
Stapled and Constrained Peptide Patents: Filing Trends and Open Claim Space
  • 80.0% concentration. The top five assignees hold 1,084 of the 1,355 records in scope — a field with almost no middle tier between the leaders and a long tail of single-filing entrants.
  • Filings cooled from a 2021 peak. Publications ran 80 in 2021 down to 45 in 2024, a 44% pullback over that span, though 2025-2026 counts are still filling in as later publications post.
  • Claim coverage is medicinal-chemistry heavy. 76.4% of records sit in A61K and 68.6% in C07K, while diagnostics-adjacent classes like G01N (7.1%) and genetic-engineering classes like C12N (4.5%) remain comparatively thin.
Get a prior-art report on your approach
1,355
Published Records
80%
Top-5 Share of All Records
-44%
Filing Growth 2021→2024
US
Leading Jurisdiction

Filing growth compares 2021 (80 records) with 2024 (45) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,355 records in scope (CR5), not by the ranked leaders only.

Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview

What the dataset covers

This landscape covers 1,355 patent families published between 2015 and mid-2026 that combine stapled-peptide or hydrocarbon-staple claim language with functional claims around alpha helicity, protease resistance, cell uptake, staple positioning, membrane lysis risk or target interface coverage. The scope is deliberately narrow: it captures work that treats the peptide staple as a functional design variable, not every macrocyclic peptide filing in the broader field.

Records concentrate around therapeutic peptide chemistry rather than diagnostic or agricultural use, and receiving-office data shows the United States, Europe and the WIPO PCT route carrying the bulk of filings, with Australia, Canada and Israel forming a secondary tier of national-phase entries.

Filing activity and technology composition, 2017-2026
  1. 1DANA FARBER CANCER INSTITUTE INC433
  2. 2INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP283
  3. 3AILERON THERAPEUTICS INC205
  4. 4PRESIDENT & FELLOWS OF HARVARD COLLEGE118
  5. 5SPITFIRE PHARMA LLC45
  6. 6MEDERIS DIABETES LLC27
  7. 7UNIVERSITY OF CHICAGO26
  8. 8DIMARCHI RICHARD D21
  9. 9ICD THERAPEUTICS GMBH17
  10. 10RED QUEEN THERAPEUTICS INC17
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Stapled and Constrained Peptides covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Let an AI agent run this analysis on your own technology

Pick a task. Every answer cites the patents behind it.

10,000 free credits to start
Data

Filing trend and technology composition

Two views of the same 1,355-record dataset: publication volume by year, and the IPC subclasses those records are tagged with.

Publications climbed to a 2021 peak, then eased

Annual publications rose from 74 in 2017 to a peak of 80 in 2021, then declined to 45 by 2024 — a 44% drop across that three-year window. Counts for 2025 and 2026 are not yet comparable, since publication typically lags filing by around 18 months and those years are still being backfilled.

Publications climbed to a 2021 peak, then eased020406080742017201820192020802021202220232024202592026Most recent year is partial — publication lag means later filings are not yet visible.

Medicinal preparations and peptide chemistry dominate

A61K (medicinal preparations) and C07K (peptides and proteins) each cover more than two-thirds of records, confirming this is primarily a therapeutic-chemistry field. A61P (therapeutic activity) appears on over a third of records, while analytical (G01N), genetic-engineering (C12N), enzyme/DNA measurement (C12Q), agrochemical (A01N) and condensation-polymer (C08G) classes each sit under 8%, marking them as secondary or emerging claim territory rather than core ground.

Medicinal preparations and peptide chemistry dominateA61K · Medicinal preparations1,03576.4%C07K · Peptides & proteins92968.6%A61P · Therapeutic activity of compou…49236.3%G01N · Material analysis & testing967.1%C12N · Microorganisms & genetic engin…614.5%C12Q · Measuring & testing involving …231.7%A01N · Biocides / agrochemicals191.4%C08G · Condensation polymers171.3%Other705.2%

Shares are the percentage of the 1,355 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.

Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Stapled and Constrained Peptides covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.

Go deeper on Stapled and Constrained Peptides with Eureka

This page is one run against one query. Ask Eureka your own question about stapled and constrained peptides and every answer comes back with the patent numbers behind it.

Try Eureka
Key Patents

The most-cited prior art in this space

Representative Filing
US20210061856A12021-03-04

Cell-permeable stapled peptide modules for cellular delivery

DANA-FARBER CANCER INSTITUTE, INC.

The disclosure relates to cell-permeable stabilized peptide modules and methods of use for e.g., cellular delivery of cargoes.Filed as US20210061856A1, assigned to Dana-Farber Cancer Institute, Inc., published 2021-03-04.

US20210061856A1 — patent drawing 1US20210061856A1 — patent drawing 2
View full filing
Highest-citation records in scope
#Publication no.Patent titleCitations
1WO2009155258A2Glucagon/GLP-1 receptor co-agonists426
2WO2011075393A2Glucagon/GLP-1 receptor co-agonists293
3US20050250680A1Stabilized alpha helical peptides and uses thereof291
4WO2005044839A2Stabilized alpha helical peptides and uses thereof262
5WO2010148089A1GIP receptor-active glucagon compounds255
6WO2011094337A1Glucagon antagonist - GIP agonist conjugates and compositions for the treatment of metabolic disorders and ob…231
7WO2009099763A1Ester-based peptide prodrugs229
8WO2010071807A1Amide based glucagon superfamily peptide prodrugs202
9WO2012088116A2Glucagon analogs exhibiting GIP receptor activity190
10US7202332B2Methods for preparing internally constrained peptides and peptidomimetics172

Citation counts reflect influence within the searched corpus and skew toward older filings; they are not a measure of current commercial relevance.

Each row carries its publication number; clicking a row searches Eureka by that number.

Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Stapled and Constrained Peptides covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself

Put your own technology through the same analysis


  
Where to run it
Fastest

Eureka on the web

When you want the answer in the next five minutes.

The agent works the prompt against patents and technical literature, citing every source.

Run your analysis now →
For builders

MCP server & REST API

When it has to run inside your own pipeline.

Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.

Browse MCP servers →
Insights

What the numbers mean for a filing decision

Three patterns stand out once volume, concentration and claim composition are read together.

Concentration
80.0% / top 5
share of all 1,355 records

A small group controls most of the family count

The top five assignees account for 1,084 of the 1,355 records in scope, and the top ten reach 88.0%. There is essentially no independent mid-tier: after the leaders, the ranking drops quickly toward single-digit filers, meaning freedom-to-operate work has to focus on a handful of portfolios rather than a broad competitive field.

Based on the assignee ranking of 100 companies
Momentum
80 → 45
publications, 2021 to 2024

Publication volume has pulled back from its peak

Annual publications fell 44% from 80 in 2021 to 45 in 2024, the most recent year that can be read as complete. Several of the largest assignees show flat or declining recent-year output, which is consistent with a field where the core staple-chemistry claims have already been staked out rather than one that has stopped attracting interest.

2025-2026 figures are still filling in due to publication lag
Claim composition
76.4% A61K
of 1,355 records

Coverage sits in medicinal chemistry, not adjacent disciplines

A61K and C07K between them tag over two-thirds of records each, showing the dominant claim style is therapeutic composition and peptide structure. Classes tied to analytical methods, genetic engineering or agrochemical use each cover under 8% of records, which is a narrower base than the core chemistry classes and worth checking before assuming it is crowded.

Class shares sum above 100% because records carry multiple IPC codes
Eureka AI Agent
Looking for what nobody has claimed yet?

Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to stapled and constrained peptides, with the prior art for and against each one.

Find the white space →
Co-filing concentrates around a small number of institutional pairs
AssigneeCo-assigneeShared families
Dana-Farber Cancer Institute, Inc.President and Fellows of Harvard College71
Indiana University Research & Technology CorporationDIMARCHI RICHARD D21
Indiana University Research & Technology CorporationF. Hoffmann-La Roche Ltd20
Dana-Farber Cancer Institute, Inc.WALENSKY LOREN D13
DIMARCHI RICHARD DSMILEY DAVID L12
Indiana University Research & Technology CorporationNovo Nordisk A/S10
Aileron Therapeutics, Inc.NASH HUW M10
WALENSKY LOREN DBIRD GREGORY H10

Ten co-assignee pairs appear in the data, and the strongest single pairing accounts for 71 shared records — evidence that a handful of academic-industry relationships, not broad cross-licensing, structured much of the earliest claim territory.

Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Stapled and Constrained Peptides covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players

Who holds the ground, and where it is still open

The leader board is short and steep; most of the technical variety in this field lives outside the top ranks.

Leader
433 records
single largest assignee

One assignee holds close to a third of the field

The leading assignee's 433 records dwarf the fifth-place holder's 45, an order-of-magnitude gap that is unusual even for concentrated pharma patent fields. Recent-year momentum data shows this assignee still filing, albeit at a reduced pace year over year, so the position is being defended rather than abandoned.

Compare against the fifth-place total of 45 records
Academic anchor
71 shared records
strongest co-assignee pair

University-institute pairings built the early portfolio

The strongest co-assignee relationship in the dataset links two academic and research institutions across 71 shared records, with a second pairing involving an individual inventor and a university technology-transfer office reaching 21. This points to foundational staple-chemistry IP originating in academic labs before later commercial licensing.

Based on the 10 co-assignee pairs identified in the data
Long tail
12.0% remainder
outside the top 10 assignees

Most named organisations hold only a handful of filings

Beyond the top ten assignees, who together already hold 88.0% of all 1,355 records, the remaining ranked companies each contribute small counts. That long tail is where niche applications — delivery mechanisms, non-oncology indications, agrochemical uses — tend to surface, even though none of them yet rival the leaders' volume.

Ranking covers 100 companies total
🔍
Sub-areas that look under-claimed relative to the core chemistry
Based on IPC classes with low record share against the 1,355-record base, these branches carry lighter claim density than A61K/C07K core chemistry.
Staple-assisted membrane-lysis risk assaysAgrochemical stapled-peptide biocidesEnzyme/DNA co-detection with stapled probesCondensation-polymer staple linker chemistriesGenetic-engineering delivery of staple constructs
Rank all filers by momentum →
Recent-year filing momentum by assignee
AssigneeRecent yearYoY
Dana-Farber Cancer Institute, Inc.3-70%
Indiana University Research & Technology Corporation0—
Aileron Therapeutics, Inc.0—
President and Fellows of Harvard College0-100%
SPITFIRE PHARMA LLC0-100%
DIMARCHI RICHARD D0—
WALENSKY LOREN D0—
University of Chicago0-100%
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Stapled and Constrained Peptides covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next

Where to take this analysis

The landscape narrows down to specific questions once a filing or freedom-to-operate decision is on the table.

Check a specific claim against the leader's portfolio

With one assignee holding 433 of 1,355 records, any new filing in core staple chemistry should be checked against that portfolio's claim scope before drafting begins.

Run a claim comparison in Eureka

Track the under-claimed branches before they fill in

Classes like G01N, C12N and C08G sit under 8% of records each; monitoring new filings there flags whether the white space is closing.

Set up monitoring in Eureka

Map the co-assignee network for licensing context

Ten identified co-assignee pairs, including one at 71 shared records, suggest existing academic-industry licensing structures worth understanding before approaching a target.

Explore assignee networks in Eureka
Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Stapled and Constrained Peptides covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ

Common questions about stapled peptide patents

Answers are grounded in the same dataset. Derived from a Patsnap search on Stapled and Constrained Peptides covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Research Stapled and Constrained Peptides in depth with Eureka

Go past this page: query the whole stapled and constrained peptides corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.

Try Eureka

Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.

Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.

Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.